Sinohealth Holdings Valuation
Is 2361 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2361?
Other financial metrics that can be useful for relative valuation.
|What is 2361's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2361's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
2192 Medlive Technology
2276 Shanghai Conant Optical
1931 IVD Medical Holding
1846 EuroEyes International Eye Clinic
2361 Sinohealth Holdings
Price-To-Earnings vs Peers: 2361 is good value based on its Price-To-Earnings Ratio (30.1x) compared to the peer average (42.1x).
Price to Earnings Ratio vs Industry
How does 2361's PE Ratio compare vs other companies in the Asian Healthcare Services Industry?
Price to Earnings Ratio vs Fair Ratio
What is 2361's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||30.1x|
|Fair PE Ratio||16.4x|
Price-To-Earnings vs Fair Ratio: 2361 is expensive based on its Price-To-Earnings Ratio (30.1x) compared to the estimated Fair Price-To-Earnings Ratio (16.4x).
Share Price vs Fair Value
What is the Fair Price of 2361 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2361 (HK$5.06) is trading above our estimate of fair value (HK$0.31)
Significantly Below Fair Value: 2361 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.